Coloplast A/S (OTCMKTS:CLPBY – Get Rating)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $11.71 and last traded at $11.83, with a volume of 147747 shares changing hands. The stock had previously closed at $12.10.
CLPBY has been the topic of several recent analyst reports. DNB Markets upgraded Coloplast A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, January 26th. JPMorgan Chase & Co. decreased their price target on shares of Coloplast A/S from 1,014.00 to 980.00 and set a “neutral” rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $1,038.00.
The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.90 and a current ratio of 1.29. The company has a market cap of $25.55 billion, a PE ratio of 40.33 and a beta of 0.28. The stock’s 50 day moving average price is $14.43 and its 200-day moving average price is $15.44.
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
- Get a free copy of the StockNews.com research report on Coloplast A/S (CLPBY)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.